Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Albusomatropin - Teva Pharmaceutical Industries

Drug Profile

Albusomatropin - Teva Pharmaceutical Industries

Alternative Names: Albumin/somatropin fusion protein; Albutropin; Human Growth Hormone Therapy - Teva; Somatropin/albumin fusion protein; TV-1106

Latest Information Update: 30 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CoGenesys
  • Developer Teva Pharmaceutical Industries
  • Class Growth hormones
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Somatotropin deficiency

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 10 May 2016 Teva Pharmaceutical terminates a phase II trial in Somatotropin deficiency (In children, Treatment-naive) in Bulgaria, Belarus, Czech Republic, Greece, Hungary, Romania, Russia, Ukraine, Serbia, Spain, Georgia, Poland, Israel and Turkey (NCT02092077)
  • 01 Apr 2016 Teva terminates a phase III trial in Somatotropin deficiency (In adults) in USA (SC) (NCT02410356)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top